Global Polio Vaccines Market

Polio Vaccines Comprehensive Study by Type (IPV (Inactivated Poliovirus Vaccine), OPV (Oral Polio Vaccine)), Application (Hospital, Clinics, Public Services, Others) Players and Region - Global Market Outlook to 2026

Polio Vaccines Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Poliomyelitis is highly contiguous disease caused by poliovirus. The virus may be transmitted primarily via the fecal-oral route, by ingesting contaminated food or water and less commonly through oral-oral route. Those who are infected may spread the disease for up to 6 weeks even if no symptoms are present. Poliovirus colonizes the gastrointestinal tract, specifically intestine and oropharynx and after about a week, it invades local lymphoid tissue and enters bloodstream, and then may infect cells of the central nervous system.This growth is primarily driven by Rise in Infectious Diseases, Increasing Government Initiative’s and Support For Polio Vaccine in Various Region and High Focus on Immunization Program Around the Globe.

Globally, a noticeable market trend is evident Cessation of Oral Polio Vaccine . Major Players, such as Astellas Pharma (Japan), GlaxoSmithKline (United Kingdom), Sanofi (France), Merck & Co (United States), Pfizer (United States), Serum Institute of India (India), EuBiological (South Korea), Bibcol (India), Vabiotech (Vietnam), Beijing Tiantan Biological Products Corp (China), Panacea Biotec Ltd (India), Bio-Med (India) and Halfkin Bio-Pharmaceuticals (India) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

The demand for vaccine market are governments of industrialized and developing countries, pooled procurement agencies, the private sector, and the various regulatory and advisory bodies overseeing vaccine quality and safety. The high income countries constitutes 82% of the global vaccine sales in terms of value. According to WHO, about 80% of global vaccine sales from five large multinational corporation that were the product of various mergers and acquisitions of pharmaceutical companies over the past decades. While maintaining a strong focus on vaccines for industrialized country markets, MNCs also sell their products in developing countries and emerging markets and participate in Global Health Initiatives

Regulatory Insights:
WHO ensures the safety and quality of vaccine and works closely on global standards which are developed and made readily available. WHO provides norms and standard and give advice to procurement agencies and countries on the acceptability, in principle of vaccines. It has also established the Global Advisory committee on vaccine safety which includes national experts and authority to support vaccine safety.

Market Drivers
  • Rise in Infectious Diseases
  • Increasing Government Initiative’s and Support For Polio Vaccine in Various Region
  • High Focus on Immunization Program Around the Globe

Market Trend
  • Cessation of Oral Polio Vaccine
  • Ensuring Vaccination in Conflict Zones and Countries with Weak Health Systems

Restraints
  • High Cost Involved in Polio Vaccine Development

Opportunities
High Growth Prospectus in Various Regions Due to Increasing Infection and Focus on Therapeutic Vaccines
Challenges
Lack of Effective Cold Chain Logistic

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Polio Vaccines Study Sheds Light on
— The Polio Vaccines Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Polio Vaccines industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Polio Vaccines industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • IPV (Inactivated Poliovirus Vaccine)
  • OPV (Oral Polio Vaccine)
By Application
  • Hospital
  • Clinics
  • Public Services
  • Others
By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rise in Infectious Diseases
      • 3.2.2. Increasing Government Initiative’s and Support For Polio Vaccine in Various Region
      • 3.2.3. High Focus on Immunization Program Around the Globe
    • 3.3. Market Challenges
      • 3.3.1. Lack of Effective Cold Chain Logistic
    • 3.4. Market Trends
      • 3.4.1. Cessation of Oral Polio Vaccine
      • 3.4.2. Ensuring Vaccination in Conflict Zones and Countries with Weak Health Systems
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Polio Vaccines, by Type, Application and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Polio Vaccines (Value)
      • 5.2.1. Global Polio Vaccines by: Type (Value)
        • 5.2.1.1. IPV (Inactivated Poliovirus Vaccine)
        • 5.2.1.2. OPV (Oral Polio Vaccine)
      • 5.2.2. Global Polio Vaccines by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Clinics
        • 5.2.2.3. Public Services
        • 5.2.2.4. Others
      • 5.2.3. Global Polio Vaccines Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
    • 5.3. Global Polio Vaccines (Volume)
      • 5.3.1. Global Polio Vaccines by: Type (Volume)
        • 5.3.1.1. IPV (Inactivated Poliovirus Vaccine)
        • 5.3.1.2. OPV (Oral Polio Vaccine)
      • 5.3.2. Global Polio Vaccines by: Application (Volume)
        • 5.3.2.1. Hospital
        • 5.3.2.2. Clinics
        • 5.3.2.3. Public Services
        • 5.3.2.4. Others
      • 5.3.3. Global Polio Vaccines Region
        • 5.3.3.1. South America
          • 5.3.3.1.1. Brazil
          • 5.3.3.1.2. Argentina
          • 5.3.3.1.3. Rest of South America
        • 5.3.3.2. Asia Pacific
          • 5.3.3.2.1. China
          • 5.3.3.2.2. Japan
          • 5.3.3.2.3. India
          • 5.3.3.2.4. South Korea
          • 5.3.3.2.5. Taiwan
          • 5.3.3.2.6. Australia
          • 5.3.3.2.7. Rest of Asia-Pacific
        • 5.3.3.3. Europe
          • 5.3.3.3.1. Germany
          • 5.3.3.3.2. France
          • 5.3.3.3.3. Italy
          • 5.3.3.3.4. United Kingdom
          • 5.3.3.3.5. Netherlands
          • 5.3.3.3.6. Rest of Europe
        • 5.3.3.4. MEA
          • 5.3.3.4.1. Middle East
          • 5.3.3.4.2. Africa
        • 5.3.3.5. North America
          • 5.3.3.5.1. United States
          • 5.3.3.5.2. Canada
          • 5.3.3.5.3. Mexico
    • 5.4. Global Polio Vaccines (Price)
      • 5.4.1. Global Polio Vaccines by: Type (Price)
  • 6. Polio Vaccines: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Astellas Pharma (Japan)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Sanofi (France)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Serum Institute of India (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. EuBiological (South Korea)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Bibcol (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Vabiotech (Vietnam)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Beijing Tiantan Biological Products Corp (China)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Panacea Biotec Ltd (India)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Bio-Med (India)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Halfkin Bio-Pharmaceuticals (India)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
  • 7. Global Polio Vaccines Sale, by Type, Application and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Polio Vaccines (Value)
      • 7.2.1. Global Polio Vaccines by: Type (Value)
        • 7.2.1.1. IPV (Inactivated Poliovirus Vaccine)
        • 7.2.1.2. OPV (Oral Polio Vaccine)
      • 7.2.2. Global Polio Vaccines by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Clinics
        • 7.2.2.3. Public Services
        • 7.2.2.4. Others
      • 7.2.3. Global Polio Vaccines Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
    • 7.3. Global Polio Vaccines (Volume)
      • 7.3.1. Global Polio Vaccines by: Type (Volume)
        • 7.3.1.1. IPV (Inactivated Poliovirus Vaccine)
        • 7.3.1.2. OPV (Oral Polio Vaccine)
      • 7.3.2. Global Polio Vaccines by: Application (Volume)
        • 7.3.2.1. Hospital
        • 7.3.2.2. Clinics
        • 7.3.2.3. Public Services
        • 7.3.2.4. Others
      • 7.3.3. Global Polio Vaccines Region
        • 7.3.3.1. South America
          • 7.3.3.1.1. Brazil
          • 7.3.3.1.2. Argentina
          • 7.3.3.1.3. Rest of South America
        • 7.3.3.2. Asia Pacific
          • 7.3.3.2.1. China
          • 7.3.3.2.2. Japan
          • 7.3.3.2.3. India
          • 7.3.3.2.4. South Korea
          • 7.3.3.2.5. Taiwan
          • 7.3.3.2.6. Australia
          • 7.3.3.2.7. Rest of Asia-Pacific
        • 7.3.3.3. Europe
          • 7.3.3.3.1. Germany
          • 7.3.3.3.2. France
          • 7.3.3.3.3. Italy
          • 7.3.3.3.4. United Kingdom
          • 7.3.3.3.5. Netherlands
          • 7.3.3.3.6. Rest of Europe
        • 7.3.3.4. MEA
          • 7.3.3.4.1. Middle East
          • 7.3.3.4.2. Africa
        • 7.3.3.5. North America
          • 7.3.3.5.1. United States
          • 7.3.3.5.2. Canada
          • 7.3.3.5.3. Mexico
    • 7.4. Global Polio Vaccines (Price)
      • 7.4.1. Global Polio Vaccines by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Polio Vaccines: by Type(USD Million)
  • Table 2. Polio Vaccines IPV (Inactivated Poliovirus Vaccine) , by Region USD Million (2015-2020)
  • Table 3. Polio Vaccines OPV (Oral Polio Vaccine) , by Region USD Million (2015-2020)
  • Table 4. Polio Vaccines: by Application(USD Million)
  • Table 5. Polio Vaccines Hospital , by Region USD Million (2015-2020)
  • Table 6. Polio Vaccines Clinics , by Region USD Million (2015-2020)
  • Table 7. Polio Vaccines Public Services , by Region USD Million (2015-2020)
  • Table 8. Polio Vaccines Others , by Region USD Million (2015-2020)
  • Table 9. South America Polio Vaccines, by Country USD Million (2015-2020)
  • Table 10. South America Polio Vaccines, by Type USD Million (2015-2020)
  • Table 11. South America Polio Vaccines, by Application USD Million (2015-2020)
  • Table 12. Brazil Polio Vaccines, by Type USD Million (2015-2020)
  • Table 13. Brazil Polio Vaccines, by Application USD Million (2015-2020)
  • Table 14. Argentina Polio Vaccines, by Type USD Million (2015-2020)
  • Table 15. Argentina Polio Vaccines, by Application USD Million (2015-2020)
  • Table 16. Rest of South America Polio Vaccines, by Type USD Million (2015-2020)
  • Table 17. Rest of South America Polio Vaccines, by Application USD Million (2015-2020)
  • Table 18. Asia Pacific Polio Vaccines, by Country USD Million (2015-2020)
  • Table 19. Asia Pacific Polio Vaccines, by Type USD Million (2015-2020)
  • Table 20. Asia Pacific Polio Vaccines, by Application USD Million (2015-2020)
  • Table 21. China Polio Vaccines, by Type USD Million (2015-2020)
  • Table 22. China Polio Vaccines, by Application USD Million (2015-2020)
  • Table 23. Japan Polio Vaccines, by Type USD Million (2015-2020)
  • Table 24. Japan Polio Vaccines, by Application USD Million (2015-2020)
  • Table 25. India Polio Vaccines, by Type USD Million (2015-2020)
  • Table 26. India Polio Vaccines, by Application USD Million (2015-2020)
  • Table 27. South Korea Polio Vaccines, by Type USD Million (2015-2020)
  • Table 28. South Korea Polio Vaccines, by Application USD Million (2015-2020)
  • Table 29. Taiwan Polio Vaccines, by Type USD Million (2015-2020)
  • Table 30. Taiwan Polio Vaccines, by Application USD Million (2015-2020)
  • Table 31. Australia Polio Vaccines, by Type USD Million (2015-2020)
  • Table 32. Australia Polio Vaccines, by Application USD Million (2015-2020)
  • Table 33. Rest of Asia-Pacific Polio Vaccines, by Type USD Million (2015-2020)
  • Table 34. Rest of Asia-Pacific Polio Vaccines, by Application USD Million (2015-2020)
  • Table 35. Europe Polio Vaccines, by Country USD Million (2015-2020)
  • Table 36. Europe Polio Vaccines, by Type USD Million (2015-2020)
  • Table 37. Europe Polio Vaccines, by Application USD Million (2015-2020)
  • Table 38. Germany Polio Vaccines, by Type USD Million (2015-2020)
  • Table 39. Germany Polio Vaccines, by Application USD Million (2015-2020)
  • Table 40. France Polio Vaccines, by Type USD Million (2015-2020)
  • Table 41. France Polio Vaccines, by Application USD Million (2015-2020)
  • Table 42. Italy Polio Vaccines, by Type USD Million (2015-2020)
  • Table 43. Italy Polio Vaccines, by Application USD Million (2015-2020)
  • Table 44. United Kingdom Polio Vaccines, by Type USD Million (2015-2020)
  • Table 45. United Kingdom Polio Vaccines, by Application USD Million (2015-2020)
  • Table 46. Netherlands Polio Vaccines, by Type USD Million (2015-2020)
  • Table 47. Netherlands Polio Vaccines, by Application USD Million (2015-2020)
  • Table 48. Rest of Europe Polio Vaccines, by Type USD Million (2015-2020)
  • Table 49. Rest of Europe Polio Vaccines, by Application USD Million (2015-2020)
  • Table 50. MEA Polio Vaccines, by Country USD Million (2015-2020)
  • Table 51. MEA Polio Vaccines, by Type USD Million (2015-2020)
  • Table 52. MEA Polio Vaccines, by Application USD Million (2015-2020)
  • Table 53. Middle East Polio Vaccines, by Type USD Million (2015-2020)
  • Table 54. Middle East Polio Vaccines, by Application USD Million (2015-2020)
  • Table 55. Africa Polio Vaccines, by Type USD Million (2015-2020)
  • Table 56. Africa Polio Vaccines, by Application USD Million (2015-2020)
  • Table 57. North America Polio Vaccines, by Country USD Million (2015-2020)
  • Table 58. North America Polio Vaccines, by Type USD Million (2015-2020)
  • Table 59. North America Polio Vaccines, by Application USD Million (2015-2020)
  • Table 60. United States Polio Vaccines, by Type USD Million (2015-2020)
  • Table 61. United States Polio Vaccines, by Application USD Million (2015-2020)
  • Table 62. Canada Polio Vaccines, by Type USD Million (2015-2020)
  • Table 63. Canada Polio Vaccines, by Application USD Million (2015-2020)
  • Table 64. Mexico Polio Vaccines, by Type USD Million (2015-2020)
  • Table 65. Mexico Polio Vaccines, by Application USD Million (2015-2020)
  • Table 66. Polio Vaccines Sales: by Type(K Unit)
  • Table 67. Polio Vaccines Sales IPV (Inactivated Poliovirus Vaccine) , by Region K Unit (2015-2020)
  • Table 68. Polio Vaccines Sales OPV (Oral Polio Vaccine) , by Region K Unit (2015-2020)
  • Table 69. Polio Vaccines Sales: by Application(K Unit)
  • Table 70. Polio Vaccines Sales Hospital , by Region K Unit (2015-2020)
  • Table 71. Polio Vaccines Sales Clinics , by Region K Unit (2015-2020)
  • Table 72. Polio Vaccines Sales Public Services , by Region K Unit (2015-2020)
  • Table 73. Polio Vaccines Sales Others , by Region K Unit (2015-2020)
  • Table 74. South America Polio Vaccines Sales, by Country K Unit (2015-2020)
  • Table 75. South America Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 76. South America Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 77. Brazil Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 78. Brazil Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 79. Argentina Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 80. Argentina Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 81. Rest of South America Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 82. Rest of South America Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 83. Asia Pacific Polio Vaccines Sales, by Country K Unit (2015-2020)
  • Table 84. Asia Pacific Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 85. Asia Pacific Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 86. China Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 87. China Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 88. Japan Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 89. Japan Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 90. India Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 91. India Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 92. South Korea Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 93. South Korea Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 94. Taiwan Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 95. Taiwan Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 96. Australia Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 97. Australia Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 98. Rest of Asia-Pacific Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 99. Rest of Asia-Pacific Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 100. Europe Polio Vaccines Sales, by Country K Unit (2015-2020)
  • Table 101. Europe Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 102. Europe Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 103. Germany Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 104. Germany Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 105. France Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 106. France Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 107. Italy Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 108. Italy Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 109. United Kingdom Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 110. United Kingdom Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 111. Netherlands Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 112. Netherlands Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 113. Rest of Europe Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 114. Rest of Europe Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 115. MEA Polio Vaccines Sales, by Country K Unit (2015-2020)
  • Table 116. MEA Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 117. MEA Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 118. Middle East Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 119. Middle East Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 120. Africa Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 121. Africa Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 122. North America Polio Vaccines Sales, by Country K Unit (2015-2020)
  • Table 123. North America Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 124. North America Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 125. United States Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 126. United States Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 127. Canada Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 128. Canada Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 129. Mexico Polio Vaccines Sales, by Type K Unit (2015-2020)
  • Table 130. Mexico Polio Vaccines Sales, by Application K Unit (2015-2020)
  • Table 131. Polio Vaccines: by Type(USD/Units)
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Company Basic Information, Sales Area and Its Competitors
  • Table 142. Company Basic Information, Sales Area and Its Competitors
  • Table 143. Company Basic Information, Sales Area and Its Competitors
  • Table 144. Company Basic Information, Sales Area and Its Competitors
  • Table 145. Polio Vaccines: by Type(USD Million)
  • Table 146. Polio Vaccines IPV (Inactivated Poliovirus Vaccine) , by Region USD Million (2021-2026)
  • Table 147. Polio Vaccines OPV (Oral Polio Vaccine) , by Region USD Million (2021-2026)
  • Table 148. Polio Vaccines: by Application(USD Million)
  • Table 149. Polio Vaccines Hospital , by Region USD Million (2021-2026)
  • Table 150. Polio Vaccines Clinics , by Region USD Million (2021-2026)
  • Table 151. Polio Vaccines Public Services , by Region USD Million (2021-2026)
  • Table 152. Polio Vaccines Others , by Region USD Million (2021-2026)
  • Table 153. South America Polio Vaccines, by Country USD Million (2021-2026)
  • Table 154. South America Polio Vaccines, by Type USD Million (2021-2026)
  • Table 155. South America Polio Vaccines, by Application USD Million (2021-2026)
  • Table 156. Brazil Polio Vaccines, by Type USD Million (2021-2026)
  • Table 157. Brazil Polio Vaccines, by Application USD Million (2021-2026)
  • Table 158. Argentina Polio Vaccines, by Type USD Million (2021-2026)
  • Table 159. Argentina Polio Vaccines, by Application USD Million (2021-2026)
  • Table 160. Rest of South America Polio Vaccines, by Type USD Million (2021-2026)
  • Table 161. Rest of South America Polio Vaccines, by Application USD Million (2021-2026)
  • Table 162. Asia Pacific Polio Vaccines, by Country USD Million (2021-2026)
  • Table 163. Asia Pacific Polio Vaccines, by Type USD Million (2021-2026)
  • Table 164. Asia Pacific Polio Vaccines, by Application USD Million (2021-2026)
  • Table 165. China Polio Vaccines, by Type USD Million (2021-2026)
  • Table 166. China Polio Vaccines, by Application USD Million (2021-2026)
  • Table 167. Japan Polio Vaccines, by Type USD Million (2021-2026)
  • Table 168. Japan Polio Vaccines, by Application USD Million (2021-2026)
  • Table 169. India Polio Vaccines, by Type USD Million (2021-2026)
  • Table 170. India Polio Vaccines, by Application USD Million (2021-2026)
  • Table 171. South Korea Polio Vaccines, by Type USD Million (2021-2026)
  • Table 172. South Korea Polio Vaccines, by Application USD Million (2021-2026)
  • Table 173. Taiwan Polio Vaccines, by Type USD Million (2021-2026)
  • Table 174. Taiwan Polio Vaccines, by Application USD Million (2021-2026)
  • Table 175. Australia Polio Vaccines, by Type USD Million (2021-2026)
  • Table 176. Australia Polio Vaccines, by Application USD Million (2021-2026)
  • Table 177. Rest of Asia-Pacific Polio Vaccines, by Type USD Million (2021-2026)
  • Table 178. Rest of Asia-Pacific Polio Vaccines, by Application USD Million (2021-2026)
  • Table 179. Europe Polio Vaccines, by Country USD Million (2021-2026)
  • Table 180. Europe Polio Vaccines, by Type USD Million (2021-2026)
  • Table 181. Europe Polio Vaccines, by Application USD Million (2021-2026)
  • Table 182. Germany Polio Vaccines, by Type USD Million (2021-2026)
  • Table 183. Germany Polio Vaccines, by Application USD Million (2021-2026)
  • Table 184. France Polio Vaccines, by Type USD Million (2021-2026)
  • Table 185. France Polio Vaccines, by Application USD Million (2021-2026)
  • Table 186. Italy Polio Vaccines, by Type USD Million (2021-2026)
  • Table 187. Italy Polio Vaccines, by Application USD Million (2021-2026)
  • Table 188. United Kingdom Polio Vaccines, by Type USD Million (2021-2026)
  • Table 189. United Kingdom Polio Vaccines, by Application USD Million (2021-2026)
  • Table 190. Netherlands Polio Vaccines, by Type USD Million (2021-2026)
  • Table 191. Netherlands Polio Vaccines, by Application USD Million (2021-2026)
  • Table 192. Rest of Europe Polio Vaccines, by Type USD Million (2021-2026)
  • Table 193. Rest of Europe Polio Vaccines, by Application USD Million (2021-2026)
  • Table 194. MEA Polio Vaccines, by Country USD Million (2021-2026)
  • Table 195. MEA Polio Vaccines, by Type USD Million (2021-2026)
  • Table 196. MEA Polio Vaccines, by Application USD Million (2021-2026)
  • Table 197. Middle East Polio Vaccines, by Type USD Million (2021-2026)
  • Table 198. Middle East Polio Vaccines, by Application USD Million (2021-2026)
  • Table 199. Africa Polio Vaccines, by Type USD Million (2021-2026)
  • Table 200. Africa Polio Vaccines, by Application USD Million (2021-2026)
  • Table 201. North America Polio Vaccines, by Country USD Million (2021-2026)
  • Table 202. North America Polio Vaccines, by Type USD Million (2021-2026)
  • Table 203. North America Polio Vaccines, by Application USD Million (2021-2026)
  • Table 204. United States Polio Vaccines, by Type USD Million (2021-2026)
  • Table 205. United States Polio Vaccines, by Application USD Million (2021-2026)
  • Table 206. Canada Polio Vaccines, by Type USD Million (2021-2026)
  • Table 207. Canada Polio Vaccines, by Application USD Million (2021-2026)
  • Table 208. Mexico Polio Vaccines, by Type USD Million (2021-2026)
  • Table 209. Mexico Polio Vaccines, by Application USD Million (2021-2026)
  • Table 210. Polio Vaccines Sales: by Type(K Unit)
  • Table 211. Polio Vaccines Sales IPV (Inactivated Poliovirus Vaccine) , by Region K Unit (2021-2026)
  • Table 212. Polio Vaccines Sales OPV (Oral Polio Vaccine) , by Region K Unit (2021-2026)
  • Table 213. Polio Vaccines Sales: by Application(K Unit)
  • Table 214. Polio Vaccines Sales Hospital , by Region K Unit (2021-2026)
  • Table 215. Polio Vaccines Sales Clinics , by Region K Unit (2021-2026)
  • Table 216. Polio Vaccines Sales Public Services , by Region K Unit (2021-2026)
  • Table 217. Polio Vaccines Sales Others , by Region K Unit (2021-2026)
  • Table 218. South America Polio Vaccines Sales, by Country K Unit (2021-2026)
  • Table 219. South America Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 220. South America Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 221. Brazil Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 222. Brazil Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 223. Argentina Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 224. Argentina Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 225. Rest of South America Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 226. Rest of South America Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 227. Asia Pacific Polio Vaccines Sales, by Country K Unit (2021-2026)
  • Table 228. Asia Pacific Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 229. Asia Pacific Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 230. China Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 231. China Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 232. Japan Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 233. Japan Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 234. India Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 235. India Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 236. South Korea Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 237. South Korea Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 238. Taiwan Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 239. Taiwan Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 240. Australia Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 241. Australia Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 242. Rest of Asia-Pacific Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 243. Rest of Asia-Pacific Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 244. Europe Polio Vaccines Sales, by Country K Unit (2021-2026)
  • Table 245. Europe Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 246. Europe Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 247. Germany Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 248. Germany Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 249. France Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 250. France Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 251. Italy Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 252. Italy Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 253. United Kingdom Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 254. United Kingdom Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 255. Netherlands Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 256. Netherlands Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 257. Rest of Europe Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 258. Rest of Europe Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 259. MEA Polio Vaccines Sales, by Country K Unit (2021-2026)
  • Table 260. MEA Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 261. MEA Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 262. Middle East Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 263. Middle East Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 264. Africa Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 265. Africa Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 266. North America Polio Vaccines Sales, by Country K Unit (2021-2026)
  • Table 267. North America Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 268. North America Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 269. United States Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 270. United States Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 271. Canada Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 272. Canada Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 273. Mexico Polio Vaccines Sales, by Type K Unit (2021-2026)
  • Table 274. Mexico Polio Vaccines Sales, by Application K Unit (2021-2026)
  • Table 275. Polio Vaccines: by Type(USD/Units)
  • Table 276. Research Programs/Design for This Report
  • Table 277. Key Data Information from Secondary Sources
  • Table 278. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Polio Vaccines: by Type USD Million (2015-2020)
  • Figure 5. Global Polio Vaccines: by Application USD Million (2015-2020)
  • Figure 6. South America Polio Vaccines Share (%), by Country
  • Figure 7. Asia Pacific Polio Vaccines Share (%), by Country
  • Figure 8. Europe Polio Vaccines Share (%), by Country
  • Figure 9. MEA Polio Vaccines Share (%), by Country
  • Figure 10. North America Polio Vaccines Share (%), by Country
  • Figure 11. Global Polio Vaccines: by Type K Unit (2015-2020)
  • Figure 12. Global Polio Vaccines: by Application K Unit (2015-2020)
  • Figure 13. South America Polio Vaccines Share (%), by Country
  • Figure 14. Asia Pacific Polio Vaccines Share (%), by Country
  • Figure 15. Europe Polio Vaccines Share (%), by Country
  • Figure 16. MEA Polio Vaccines Share (%), by Country
  • Figure 17. North America Polio Vaccines Share (%), by Country
  • Figure 18. Global Polio Vaccines: by Type USD/Units (2015-2020)
  • Figure 19. Global Polio Vaccines share by Players 2020 (%)
  • Figure 20. Global Polio Vaccines share by Players (Top 3) 2020(%)
  • Figure 21. Global Polio Vaccines share by Players (Top 5) 2020(%)
  • Figure 22. BCG Matrix for key Companies
  • Figure 23. Astellas Pharma (Japan) Revenue, Net Income and Gross profit
  • Figure 24. Astellas Pharma (Japan) Revenue: by Geography 2020
  • Figure 25. GlaxoSmithKline (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 26. GlaxoSmithKline (United Kingdom) Revenue: by Geography 2020
  • Figure 27. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 28. Sanofi (France) Revenue: by Geography 2020
  • Figure 29. Merck & Co (United States) Revenue, Net Income and Gross profit
  • Figure 30. Merck & Co (United States) Revenue: by Geography 2020
  • Figure 31. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 32. Pfizer (United States) Revenue: by Geography 2020
  • Figure 33. Serum Institute of India (India) Revenue, Net Income and Gross profit
  • Figure 34. Serum Institute of India (India) Revenue: by Geography 2020
  • Figure 35. EuBiological (South Korea) Revenue, Net Income and Gross profit
  • Figure 36. EuBiological (South Korea) Revenue: by Geography 2020
  • Figure 37. Bibcol (India) Revenue, Net Income and Gross profit
  • Figure 38. Bibcol (India) Revenue: by Geography 2020
  • Figure 39. Vabiotech (Vietnam) Revenue, Net Income and Gross profit
  • Figure 40. Vabiotech (Vietnam) Revenue: by Geography 2020
  • Figure 41. Beijing Tiantan Biological Products Corp (China) Revenue, Net Income and Gross profit
  • Figure 42. Beijing Tiantan Biological Products Corp (China) Revenue: by Geography 2020
  • Figure 43. Panacea Biotec Ltd (India) Revenue, Net Income and Gross profit
  • Figure 44. Panacea Biotec Ltd (India) Revenue: by Geography 2020
  • Figure 45. Bio-Med (India) Revenue, Net Income and Gross profit
  • Figure 46. Bio-Med (India) Revenue: by Geography 2020
  • Figure 47. Halfkin Bio-Pharmaceuticals (India) Revenue, Net Income and Gross profit
  • Figure 48. Halfkin Bio-Pharmaceuticals (India) Revenue: by Geography 2020
  • Figure 49. Global Polio Vaccines: by Type USD Million (2021-2026)
  • Figure 50. Global Polio Vaccines: by Application USD Million (2021-2026)
  • Figure 51. South America Polio Vaccines Share (%), by Country
  • Figure 52. Asia Pacific Polio Vaccines Share (%), by Country
  • Figure 53. Europe Polio Vaccines Share (%), by Country
  • Figure 54. MEA Polio Vaccines Share (%), by Country
  • Figure 55. North America Polio Vaccines Share (%), by Country
  • Figure 56. Global Polio Vaccines: by Type K Unit (2021-2026)
  • Figure 57. Global Polio Vaccines: by Application K Unit (2021-2026)
  • Figure 58. South America Polio Vaccines Share (%), by Country
  • Figure 59. Asia Pacific Polio Vaccines Share (%), by Country
  • Figure 60. Europe Polio Vaccines Share (%), by Country
  • Figure 61. MEA Polio Vaccines Share (%), by Country
  • Figure 62. North America Polio Vaccines Share (%), by Country
  • Figure 63. Global Polio Vaccines: by Type USD/Units (2021-2026)
List of companies from research coverage that are profiled in the study
  • Astellas Pharma (Japan)
  • GlaxoSmithKline (United Kingdom)
  • Sanofi (France)
  • Merck & Co (United States)
  • Pfizer (United States)
  • Serum Institute of India (India)
  • EuBiological (South Korea)
  • Bibcol (India)
  • Vabiotech (Vietnam)
  • Beijing Tiantan Biological Products Corp (China)
  • Panacea Biotec Ltd (India)
  • Bio-Med (India)
  • Halfkin Bio-Pharmaceuticals (India)
Additional players considered in the study are as follows:
Tiantan Biological (China) , Sinovac Biotech Ltd (China) , Halfkin Bio-Pharmaceuticals Corporation Ltd (India)
Select User Access Type

Key Highlights of Report


Jul 2021 239 Pages 75 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Polio Vaccines Market Quantitative research analysis
Global Polio Vaccines Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Historical year: 2016-2020; Base year: 2020; Forecast period: 2021 to 2026
Companies that are profiled in Global Polio Vaccines Market are Astellas Pharma (Japan), GlaxoSmithKline (United Kingdom), Sanofi (France), Merck & Co (United States), Pfizer (United States), Serum Institute of India (India), EuBiological (South Korea), Bibcol (India), Vabiotech (Vietnam), Beijing Tiantan Biological Products Corp (China), Panacea Biotec Ltd (India), Bio-Med (India) and Halfkin Bio-Pharmaceuticals (India) etc.
Poliomyelitis is highly contiguous disease caused by poliovirus. The virus may be transmitted primarily via the fecal-oral route, by ingesting contaminated food or water and less commonly through oral-oral route. Those who are infected may spread the disease for up to 6 weeks even if no symptoms are present. Poliovirus colonizes the gastrointestinal tract, specifically intestine and oropharynx and after about a week, it invades local lymphoid tissue and enters bloodstream, and then may infect cells of the central nervous system.

Know More About Global Polio Vaccines Market Report?

Have a Query? Click Here

Other Related Reports

Impetigo Drug Comprehensive Study by Type (FMX-102, LTX-109, Mupirocin, Ozenoxacin, Others), Route of Administration (Topical, Oral), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail ...
$ 3500
Clomifene Citrate Comprehensive Study by Application (Hospital, Clinics, Fertility Center), Form (Tablet, Injection), Distribution Channel (Hospital Pharmacies, Medical Stores, Online Pharmacies), En...
$ 3800
Frankincense Oil Comprehensive Study by Type (Natural Frankincense Oil, Synthetic Frankincense Oil), Application (Medicine, Skin care, Oral Care , Others), Distribution Channel (Direct, Indirect (Spe...
$ 3500
Pycnogenol Comprehensive Study by Application (Nutraceutical, Personal and Skin Care Products, Food and Beverages, Health Supplements, Others), Distribution Channel (Direct Sale (Online, Offline), Di...
$ 3450
Protein Kinase Inhibitor Comprehensive Study by Type (Serine/Threonine Protein Kinase Inhibitors, Tyrosine Protein Kinase Inhibitor), Application (Lung Cancer, Breast Cancer, Renal Cell Cancer, Other...
$ 3750
Raloxifene Hydrochloride Comprehensive Study by Type (Tablet, Capsule), Application (Pharmaceuticals, Chemicals, Others), End-users (Hospitals, Clinics, Others), Distribution Channel (Online Channels...
$ 3800